AU2009251519A1 - Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator - Google Patents

Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator Download PDF

Info

Publication number
AU2009251519A1
AU2009251519A1 AU2009251519A AU2009251519A AU2009251519A1 AU 2009251519 A1 AU2009251519 A1 AU 2009251519A1 AU 2009251519 A AU2009251519 A AU 2009251519A AU 2009251519 A AU2009251519 A AU 2009251519A AU 2009251519 A1 AU2009251519 A1 AU 2009251519A1
Authority
AU
Australia
Prior art keywords
hydroxy
halo
mono
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009251519A
Other languages
English (en)
Inventor
Nitin D. Sonawane
Alan S. Verkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2009251519A1 publication Critical patent/AU2009251519A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2009251519A 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator Abandoned AU2009251519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4265108P 2008-04-04 2008-04-04
US61/042,651 2008-04-04
PCT/US2009/039566 WO2009146144A2 (en) 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
AU2009251519A1 true AU2009251519A1 (en) 2009-12-03

Family

ID=41133847

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009251519A Abandoned AU2009251519A1 (en) 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator

Country Status (10)

Country Link
US (1) US20090253799A1 (https=)
EP (1) EP2288592A2 (https=)
JP (1) JP2011516499A (https=)
KR (1) KR20110004413A (https=)
AU (1) AU2009251519A1 (https=)
BR (1) BRPI0910416A2 (https=)
CA (1) CA2718676A1 (https=)
MX (1) MX2010010783A (https=)
TW (1) TW200946129A (https=)
WO (1) WO2009146144A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740532A4 (en) * 2004-03-30 2009-06-10 Univ California CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
WO2008079897A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
AU2009228307A1 (en) * 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
CN111542511A (zh) * 2017-11-02 2020-08-14 宇部兴产株式会社 蛋白分解酶的双头型抑制剂
BR112021025048A2 (pt) 2019-06-12 2022-02-01 Univ California Métodos de tratamento de diarreia por ácido biliar

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103902T1 (de) * 1982-05-07 1994-04-15 Ciba Geigy Ag Verwendung von chinolinderivaten zum schuetzen von kulturpflanzen.
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
EP1740532A4 (en) * 2004-03-30 2009-06-10 Univ California CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
WO2008079897A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Also Published As

Publication number Publication date
BRPI0910416A2 (pt) 2019-09-24
TW200946129A (en) 2009-11-16
US20090253799A1 (en) 2009-10-08
JP2011516499A (ja) 2011-05-26
WO2009146144A2 (en) 2009-12-03
WO2009146144A3 (en) 2010-01-28
MX2010010783A (es) 2010-11-12
EP2288592A2 (en) 2011-03-02
KR20110004413A (ko) 2011-01-13
CA2718676A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
AU2009251519A1 (en) Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
EP2117601A2 (en) Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US20100168112A1 (en) 2-Substituted and 4-substituted aryl nitrone compounds
MX2014013294A (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
JPH07501539A (ja) Ｎ，ｎ’−ジアセチルシスチンの有機塩
WO2016142886A2 (en) 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
CZ177596A3 (en) 2,4-disulfonylphenylbutylnitrone, salts thereof and the use of the salts as medicaments
JP2016531871A (ja) 粘膜炎を治療および／または予防するための方法および組成物
BR112013015174A2 (pt) compostos de tio-semicarbazona e aplicação no tratamento de cancer
EP2627641A1 (en) Reversal of drug-induced neuromuscular block using novel molecular containers
JP2011517674A (ja) 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤
WO2019070943A1 (en) SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF
US20240374561A1 (en) Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
JP2025509730A (ja) 循環タンパク質の選択的分解を目的とした二官能性小分子
EP3445373B1 (en) Use of thyroid beta-agonists
JP2012500271A5 (https=)
WO2002074305A1 (en) Use of a substantially cell membrane impermeable compound for treating arthritis
PT98866A (pt) Metodo de inibicao de geracao de superoxido, utilizando tioeteracidos fenolicos
CA2740568A1 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
NL8201320A (nl) Ester van mercapto-acylcarnitinen, werkwijze ter bereiding van en famaceutische preparaten, die deze esters bevatten.
WO2018100560A1 (en) Coordination compounds and formulations, preparation methods and use thereof as antiphlogistic agents
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도
CN105693577B (zh) 硫普罗宁锌及其制备方法和以该化合物为活性成分的药物组合物
WO2023069711A1 (en) Fap-targeted neutron capture agents, and uses and formulations related thereto
AU2020268749B2 (en) New therapeutic vectors and prodrugs for treating cancers

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application